Analysis Tools
cardiovascular system
|
• subcellular disorganization, with accumulation of vacuoles, mitochondria showing diversity in size, profoundly disrupted alignment, and a rounder and more densely packed appearance after tamoxifen treatment
• loss of mitochondrial cristae and smaller average mitochondria size after tamoxifen treatment
|
|
• distorted and wavy myofiber architecture 4 weeks after tamoxifen treatment
• mitochondrial deformities accompanied by electron-dense material are present after tamoxifen treatment
|
|
• elevated mitochondrial iron content but not heme levels 4 weeks after tamoxifen treatment
|
|
• 8 weeks after tamoxifen treatment
|
|
• increased left ventricular diastolic diameter at 8 weeks after tamoxifen treatment
|
|
• 8 weeks after tamoxifen treatment
|
|
• elevated lipid peroxidation and reactive oxygen species after tamoxifen treatment
|
|
• as early as 4 weeks after tamoxifen treatment
|
|
• reduced heart pump function as measured by fractional shortening and ejection fraction 4 and 8 weeks after tamoxifen treatment
• decreased strength of contraction (dP/dtmax) at 8 weeks after tamoxifen treatment
|
|
• decreased relaxation (dP/dtmin) at 8 weeks after tamoxifen treatment
|
|
• lower end systolic pressure at 8 weeks after tamoxifen treatment
|
|
• mild after tamoxifen treatment
|
homeostasis/metabolism
|
• elevated mitochondrial iron content but not heme levels 4 weeks after tamoxifen treatment
|
muscle
|
• distorted and wavy myofiber architecture 4 weeks after tamoxifen treatment
• mitochondrial deformities accompanied by electron-dense material are present after tamoxifen treatment
|
|
• reduced heart pump function as measured by fractional shortening and ejection fraction 4 and 8 weeks after tamoxifen treatment
• decreased strength of contraction (dP/dtmax) at 8 weeks after tamoxifen treatment
|
|
• decreased relaxation (dP/dtmin) at 8 weeks after tamoxifen treatment
|
|
• mild after tamoxifen treatment
|
growth/size/body
|
• 8 weeks after tamoxifen treatment
|
